Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omadacycline plus rifampicin vs doxycycline plus rifampicin for brucellosis
ChiCTR2500099844Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Mar 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of omadacycline in brucellosis (2 arms), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: Clinical effective rate. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
omadacycline
03
Conditions
brucellosis
Beyond the preview
Go deeper on ChiCTR2500099844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099844.